View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
December 18, 2018updated 12 Jul 2022 1:09pm

BeiGene enrols first patients in two Phase III tislelizumab trials

BeiGene has enrolled the first patients in two of its global Phase III clinical trials to evaluate tislelizumab for the treatment of patients with gastric cancer and esophageal cancer.

BeiGene has enrolled the first patients in two of its global Phase III clinical trials to evaluate tislelizumab for the treatment of patients with gastric cancer and esophageal cancer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Tislelizumab is currently under development as a humanised IgG4 anti–PD-1 monoclonal antibody specifically developed to reduce binding to FcγR on macrophages.

Both Phase III trials are designed to investigate tislelizumab in combination with chemotherapy as potential first-line treatments in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

It will also evaluate the response in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

The trials feature randomised, double-blind, placebo-controlled designs.

“Available data have shown promise for anti-PD-1 antibodies in patients with advanced gastric or gastroesophageal adenocarcinoma”

BeiGene Immuno-Oncology chief medical officer Amy Peterson said: “Available data have shown promise for anti-PD-1 antibodies in patients with advanced gastric or gastroesophageal adenocarcinoma and in patients with advanced esophageal carcinoma.

“Gastric and esophageal cancers are among the most common malignancies in Asia and collectively are responsible for over 800,000 deaths annually in China alone.”

The trial will enrol 720 patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Patients will be treated with either 200mg of tislelizumab or placebo combined with platinum- and fluoropyrimidine-based chemotherapy intravenously once every three weeks.

Co-primary objectives of the trial include progression-free survival (PFS) and overall survival (OS), while its secondary objectives are overall response rate (ORR), duration of response (DOR). quality of life (QoL), safety and tolerability.

The esophageal cancer trial intends to recruit 480 patients with unresectable, locally advanced recurrent, or metastatic ESCC.

The recruited patients are expected to receive either 200mg of tislelizumab or placebo in combination with platinum- and fluoropyrimidine-based chemotherapy, intravenously once every three weeks.

Co-primary objectives of the trial comprise PFS and OS, while secondary objectives include ORR, DOR, and QoL, as well as safety and tolerability.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena